sevirumab

mAbexperimental

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS. — Wikipedia

Clinical trial activity

6 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Feb 1, 1995 (NCT00004642)

Timeline

1990s

  1. Jan 1, 1995

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1995

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ev2-7
  • ev2 7 compound
  • ev2-7 compound
  • msl 109
  • msl-109
  • msl-109
  • msl-109
  • protovir
  • protovir
  • sdz msl 109
  • sdz msl 109
  • sdz msl-109
  • sdz-msl-109
  • sevirumab
  • sevirumab
  • sevirumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00000836Phase 2Nov 2, 1999National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001061Phase 2Nov 2, 1999Facet Biotech, National Institute of Allergy and Infectious Diseases (NIAID)
NCT00002016Phase 1Nov 2, 1999Sandoz
NCT00002268Phase 1Nov 2, 1999Sandoz
NCT00000135Phase 2/Phase 3 (Phase 3)Sep 1, 1995Johns Hopkins University
NCT00004642Phase 1/Phase 2 (Phase 2)Feb 1, 1995National Center for Research Resources (NCRR), National Institute of Allergy and Infectious Diseases (NIAID)
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government3211995
SandozFor profit2211999
Facet BiotechFor profit1011999
Johns Hopkins UniversityAcademic/Hospital1111995
National Center for Research Resources (NCRR)Government1111995
5 organizations
Page 1 / 1